ICUI
VENTE TOTALE: 378 titres (~68 978,12 $ US)
- Insiders
- FINNEY ELISHA W
- Total bought
- —
- Total sold
- $68,978
- Last activity
- 2026-08-11
- Last synced
-
2026-08-21 23:36:53
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-09-06
ICUI presents a compelling earnings catalyst with a significant Q2 2026 beat ($2.37 vs $1.91 EPS) and analyst upgrades, supported by growing institutional confidence, justifying a moderately elevated event-driven score.
The first sentence of the analysis written for ICUI on 2026-09-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 36.8% | 34.6% | 32.8% | 30.6% | 37.3% | |
| Ebit Margin | 4.9% | 1.7% | 1.1% | -1.9% | 9.4% | |
| Ebitda Margin | 14.6% | 1.8% | 11.2% | 8.4% | 17.0% | |
| Operating Profit Margin | 4.8% | 1.8% | 1.0% | -1.9% | 9.4% | |
| Pretax Profit Margin | 0.1% | -2.8% | -3.5% | -5.0% | 9.4% | |
| Continuous Operations Profit Margin | 0.0% | -4.9% | -1.3% | -3.3% | 7.8% | |
| Net Profit Margin | 0.0% | -4.9% | -1.3% | -3.3% | 7.8% | |
| Bottom Line Profit Margin | 0.0% | -4.9% | -1.3% | -3.3% | 7.8% | |
| Current Ratio | 2.360 | 2.593 | 2.535 | 2.498 | 5.129 | |
| Quick Ratio | 1.126 | 1.541 | 1.062 | 1.090 | 3.684 | |
| Solvency Ratio | 0.114 | -0.051 | 0.088 | 0.066 | 0.765 | |
| Cash Ratio | 0.617 | 0.555 | 0.528 | 0.422 | 2.753 | |
| Price To Earnings Ratio | 4,803.704 | -32.126 | -81.089 | -50.637 | 48.835 | |
| Price To Earnings Growth Ratio | -47.743 | -0.110 | 1.341 | 0.309 | 2.902 | |
| Forward Price To Earnings Growth Ratio | -47.743 | -0.110 | 1.341 | 0.309 | 2.902 | |
| Price To Earnings Diluted Ratio | 4,852.721 | -32.126 | -81.089 | -50.637 | 50.072 | |
| Price To Earnings Diluted Growth Ratio | -48.234 | -0.110 | 1.341 | 0.306 | 2.796 | |
| Price To Book Ratio | 1.655 | 1.926 | 1.132 | 1.798 | 3.114 | |
| Price To Sales Ratio | 1.576 | 1.589 | 1.064 | 1.649 | 3.824 | |
| Price To Free Cash Flow Ratio | 38.292 | 30.357 | 33.128 | -23.280 | 27.006 | |
| Price To Operating Cash Flow Ratio | 19.547 | 18.547 | 14.457 | -60.499 | 18.812 | |
| Debt To Assets Ratio | 0.344 | 0.391 | 0.389 | 0.384 | 0.024 | |
| Debt To Equity Ratio | 0.656 | 0.835 | 0.802 | 0.830 | 0.028 | |
| Debt To Capital Ratio | 0.396 | 0.455 | 0.445 | 0.454 | 0.027 | |
| Long Term Debt To Capital Ratio | 0.381 | 0.438 | 0.426 | 0.437 | 0.000 | |
| Financial Leverage Ratio | 1.907 | 2.139 | 2.062 | 2.161 | 1.164 | |
| Working Capital Turnover Ratio | 2.851 | 2.931 | 3.053 | 2.905 | 1.701 | |
| Operating Cash Flow Ratio | 0.361 | 0.367 | 0.345 | -0.126 | 1.333 | |
| Operating Cash Flow Sales Ratio | 0.081 | 0.086 | 0.074 | -0.027 | 0.203 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.510 | 0.611 | 0.436 | 2.599 | 0.697 | |
| Debt Service Coverage Ratio | 2.314 | -0.055 | 1.964 | 2.305 | 237.071 | |
| Interest Coverage Ratio | 1.015 | 0.403 | 0.222 | -0.606 | 143.642 | |
| Short Term Operating Cash Flow Coverage Ratio | 5.187 | 4.001 | 3.259 | -2.093 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.129 | 0.124 | 0.098 | -0.036 | 5.939 | |
| Capital Expenditure Coverage Ratio | 2.043 | 2.571 | 1.774 | -0.625 | 3.296 | |
| Dividend Paid And Capex Coverage Ratio | 2.043 | 2.571 | 1.774 | -0.625 | 3.296 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 14.086 | 119.109 | 15.215 | 27.587 | 20.251 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 36.8% | ▲2.1% | ▲2.3% |
| Ebit Margin | 4.9% | ▲3.2% | ▲1.8% |
| Ebitda Margin | 14.6% | ▲12.8% | ▲4.0% |
| Operating Profit Margin | 4.8% | ▲3.0% | ▲1.8% |
| Pretax Profit Margin | 0.1% | ▲2.9% | ▲0.5% |
| Continuous Operations Profit Margin | 0.0% | ▲5.0% | ▲0.4% |
| Net Profit Margin | 0.0% | ▲5.0% | ▲0.4% |
| Bottom Line Profit Margin | 0.0% | ▲5.0% | ▲0.4% |
| Current Ratio | 2.360 | ▼-0.232 | ▼-0.663 |
| Quick Ratio | 1.126 | ▼-0.416 | ▼-0.575 |
| Solvency Ratio | 0.114 | ▲0.165 | ▼-0.083 |
| Cash Ratio | 0.617 | ▲0.062 | ▼-0.358 |
| Price To Earnings Ratio | 4803.704 | ▲4835.830 | ▲3865.966 |
| Price To Earnings Growth Ratio | -47.743 | ▼-47.634 | ▼-39.083 |
| Forward Price To Earnings Growth Ratio | -47.743 | ▼-47.634 | ▼-39.083 |
| Price To Earnings Diluted Ratio | 4852.721 | ▲4884.847 | ▲3904.933 |
| Price To Earnings Diluted Growth Ratio | -48.234 | ▼-48.124 | ▼-39.453 |
| Price To Book Ratio | 1.655 | ▼-0.270 | ▼-0.270 |
| Price To Sales Ratio | 1.576 | ▼-0.012 | ▼-0.364 |
| Price To Free Cash Flow Ratio | 38.292 | ▲7.936 | ▲17.192 |
| Price To Operating Cash Flow Ratio | 19.547 | ▲0.999 | ▲17.374 |
| Debt To Assets Ratio | 0.344 | ▼-0.047 | ▲0.037 |
| Debt To Equity Ratio | 0.655 | ▼-0.180 | ▲0.025 |
| Debt To Capital Ratio | 0.396 | ▼-0.059 | ▲0.041 |
| Long Term Debt To Capital Ratio | 0.382 | ▼-0.057 | ▲0.045 |
| Financial Leverage Ratio | 1.907 | ▼-0.232 | ▲0.021 |
| Working Capital Turnover Ratio | 2.851 | ▼-0.080 | ▲0.163 |
| Operating Cash Flow Ratio | 0.360 | ▼-0.006 | ▼-0.095 |
| Operating Cash Flow Sales Ratio | 0.081 | ▼-0.005 | ▼-0.003 |
| Free Cash Flow Operating Cash Flow Ratio | 0.510 | ▼-0.101 | ▼-0.460 |
| Debt Service Coverage Ratio | 2.314 | ▲2.369 | ▼-46.406 |
| Interest Coverage Ratio | 1.015 | ▲0.612 | ▼-27.920 |
| Short Term Operating Cash Flow Coverage Ratio | 5.187 | ▲1.187 | ▲3.117 |
| Operating Cash Flow Coverage Ratio | 0.129 | ▲0.005 | ▼-1.122 |
| Capital Expenditure Coverage Ratio | 2.043 | ▼-0.528 | ▲0.231 |
| Dividend Paid And Capex Coverage Ratio | 2.043 | ▼-0.528 | ▲0.231 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 14.086 | ▼-105.023 | ▼-25.164 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $3.52B | $3.78B | $2.40B | $3.76B | $5.03B | |
| Enterprise value | $4.60B | $5.12B | $3.85B | $5.28B | $4.53B | |
| EV / Sales | 2.06x | 2.15x | 1.71x | 2.32x | 3.44x | |
| EV / Op. cash flow | 25.57x | 25.08x | 23.18x | -85.05x | 16.91x | |
| EV / Free cash flow | 50.10x | 41.05x | 53.12x | -32.73x | 24.28x | |
| EV / EBITDA | 14.09x | 119.11x | 15.21x | 27.59x | 20.25x | |
| Net debt / EBITDA | 3.32x | 31.03x | 5.72x | 7.96x | -2.27x | |
| Current ratio | 2.36x | 2.59x | 2.54x | 2.50x | 5.13x | |
| Income quality | 245.69x | -1.73x | -5.60x | 0.84x | 2.59x | |
| Graham number | $8 | — | — | — | $91 | |
| Graham net-net | -$48 | -$61 | -$63 | -$70 | $26 | |
| Tax burden | 23.1% | 178.3% | 37.9% | 64.9% | 83.7% | |
| Interest burden | 2.9% | -162.9% | -320.5% | 262.4% | 99.2% | |
| Working capital | $678.6M | $885.8M | $739.4M | $740.6M | $829.0M | |
| Invested capital | $3.32B | $3.56B | $3.77B | $3.89B | $1.57B | |
| Return on assets | 0.0% | -2.8% | -0.7% | -1.6% | 5.5% | |
| Operating ROA | 2.6% | 1.0% | 0.5% | -1.3% | 6.8% | |
| Return on tangible assets | 0.0% | -5.8% | -1.5% | -3.6% | 6.3% | |
| Return on equity | 0.0% | -6.0% | -1.4% | -3.6% | 6.4% | |
| Return on invested capital | 0.7% | 1.2% | 0.2% | -0.7% | 6.1% | |
| Return on capital employed | 3.0% | 1.2% | 0.6% | -1.1% | 7.3% | |
| Earnings yield | 0.0% | -3.1% | -1.2% | -2.0% | 2.0% | |
| Free cash flow yield | 2.6% | 3.3% | 3.0% | -4.3% | 3.7% | |
| Capex / Op. cash flow | 49.0% | 38.9% | 56.4% | -159.9% | 30.3% | |
| Capex / Depreciation | 43.9% | 33.0% | 40.9% | 42.2% | 90.5% | |
| Capex / Sales | 3.9% | 3.3% | 4.1% | 4.4% | 6.2% | |
| SG&A / Sales | 28.0% | 26.8% | 26.9% | 26.7% | 23.0% | |
| R&D / Sales | 3.9% | 3.7% | 3.8% | 4.1% | 3.6% | |
| Stock comp / Sales | 2.5% | 2.0% | 1.8% | 1.6% | 2.1% | |
| Intangibles / Total assets | 52.7% | 51.7% | 53.5% | 53.9% | 12.3% | |
| Days sales outstanding | 30d | 31d | 29d | 40d | 35d | |
| Days payables outstanding | 40d | 35d | 36d | 50d | 36d | |
| Operating cycle | 189d | 168d | 200d | 200d | 163d | |
| Cash conversion cycle | 149d | 133d | 164d | 150d | 127d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-7.1%EV / Sales ▼-4.0%EV / EBITDA ▼-88.2%EV / Op. cash flow ▲+0.494Earnings yield ▲+0.031
Profitability
Return on equity ▲+0.060Return on assets ▲+0.028Return on invested capital ▼-0.005Return on capital employed ▲+0.018Operating ROA ▲+0.016Income quality ▲+247.426Tax burden ▼-1.552
Efficiency
Days sales outstanding ▼-1.513Days payables outstanding ▲+5.258Operating cycle ▲+20.830Cash conversion cycle ▲+15.572Capex / Sales ▲+0.006R&D / Sales ▲+0.002
Balance-sheet strength
Current ratio ▼-0.232Net debt / EBITDA ▼-27.708Working capital ▼-207218000.000Invested capital ▼-240479000.000Intangibles / Total assets ▲+0.010
Change over 5 years
Valuation
Market cap ▼-30.2%EV / Sales ▼-40.0%EV / EBITDA ▼-30.4%EV / Op. cash flow ▲+8.661Earnings yield ▼-0.020Graham number ▼-83.728
Profitability
Return on equity ▼-0.063Return on assets ▼-0.055Return on invested capital ▼-0.054Return on capital employed ▼-0.043Operating ROA ▼-0.042Income quality ▲+243.099Tax burden ▼-0.606
Efficiency
Days sales outstanding ▼-5.064Days payables outstanding ▲+4.051Operating cycle ▲+25.884Cash conversion cycle ▲+21.833Capex / Sales ▼-0.022R&D / Sales ▲+0.003
Balance-sheet strength
Current ratio ▼-2.769Net debt / EBITDA ▲+5.593Working capital ▼-150449000.000Invested capital ▲+1746516000.000Intangibles / Total assets ▲+0.403
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2025-05-06 | Gilbert Cisneros | Sale | $1,001 - $15,000 |
| 2025-05-06 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2024-10-31 | Josh Gottheimer | Sale | $1,001 - $15,000 |
| 2022-02-14 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2020-12-23 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2020-12-21 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2020-09-25 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2020-09-24 | Gilbert Cisneros | Purchase | $15,001 - $50,000 |
| 2020-09-23 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2020-03-31 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
Recent news
- 2026-08-09 California State Teachers Retirement System Grows Position in ICU Medical, Inc. $ICUI California State Teachers Retirement System grew its stake in shares of ICU Medical, Inc. (NASDAQ: ICUI) by 25.2% during the undefined quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 27,512 shares of the medical instruments supplier''s stock after purchasing an additional 5,536 shares during the period.
- 2026-08-07 ICU Medical Analysts Boost Their Forecasts Following Upbeat Q2 Earnings ICU Medical Inc (NASDAQ:ICUI) on Thursday posted upbeat earnings for the second quarter.
- 2026-08-07 ICU Medical, Inc. (ICUI) Q2 2026 Earnings Call Transcript ICU Medical, Inc. (ICUI) Q2 2026 Earnings Call Transcript
- 2026-08-06 ICU Medical Q2 Earnings Call Highlights ICU Medical NASDAQ: ICUI reported second-quarter revenue of $548 million, up 6% organically and 1% on a reported basis, as growth in its consumables and infusion systems businesses helped offset continued pressure in Vital Care and the effects of the IV Solutions joint venture deconsolidation.
- 2026-08-06 ICU Medical (ICUI) Reports Q2 Earnings: What Key Metrics Have to Say While the top- and bottom-line numbers for ICU Medical (ICUI) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 2026-08-06 ICU Medical (ICUI) Tops Q2 Earnings and Revenue Estimates ICU Medical (ICUI) came out with quarterly earnings of $2.37 per share, beating the Zacks Consensus Estimate of $1.91 per share. This compares to earnings of $2.1 per share a year ago.
- 2026-08-06 ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance SAN CLEMENTE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended June 30, 2026.
- 2026-07-23 ICU Medical Announces Time of Second Quarter 2026 Earnings Conference Call SAN CLEMENTE, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its second quarter 2026 earnings release and conference call.
- 2026-07-09 Otsuka ICU Medical LLC Announces Over $500M Expansion of IV Solutions Manufacturing in North America This expansion of IV solutions manufacturing will help enhance supply-chain resiliency, support portfolio development and advance non-DEHP innovation for the North American IV solutions market. Joint venture announces over $500M IV solutions manufacturing expansion in Austin, TX Expansion aimed at improving IV solutions supply resiliency and quality, and accelerating non-DEHP new product development in North America via fully automated technology First major milestone toward fulfilling the commitments of the joint venture finalized in May 2025 between ICU Medical, Inc. and Otsuka Pharmaceutical Factory America, Inc. AUSTIN, Texas, July 9, 2026 /PRNewswire/ -- Otsuka ICU Medical LLC today announced plans for an over $500 million expansion to its US IV solutions manufacturing through a new facility and significant upgrades to its existing operations in Austin, Texas.
- 2026-07-08 ICUI vs. SYK: Which Stock Should Value Investors Buy Now? Investors looking for stocks in the Medical - Products sector might want to consider either ICU Medical (ICUI) or Stryker (SYK). But which of these two stocks offers value investors a better bang for their buck right now?